Sanofi (SNYNF) Net Income Growth (1y) (2010 - 2025)
Sanofi (SNYNF) Net Income Growth (1y) (2010 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
168.07% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
-52.40% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
-45.93% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
233.92% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-182.77% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
5.14% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
53.69% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
- |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Sanofi |
- |
- |
9.49 Bn |
- |
| Date | Value |
|---|
| Dec 31, 2025 |
-1,655.15% |
| Jun 30, 2025 |
6,223.19% |
| Dec 31, 2024 |
59.73% |
| Jun 30, 2024 |
-99.64% |
| Dec 31, 2023 |
-102.15% |
| Jun 30, 2023 |
0.38% |
| Dec 31, 2022 |
7,487.04% |
| Jun 30, 2022 |
6.66% |
| Dec 31, 2021 |
-77.69% |
| Jun 30, 2021 |
50.52% |
| Dec 31, 2020 |
58,804.96% |
| Jun 30, 2020 |
163.55% |
| Dec 31, 2019 |
-100.68% |
| Jun 30, 2019 |
-64.24% |
| Dec 31, 2018 |
9,276.93% |
| Jun 30, 2018 |
224.47% |
| Dec 31, 2017 |
-95,657,447.07% |
| Jun 30, 2017 |
-23.76% |
| Dec 31, 2016 |
-0.33% |
| Jun 30, 2016 |
-375.10% |
